Polyploid Giant Cancer Cells (PGCCs) have been recognized as tumor cells that are resistant to anticancer therapies. However, it remains unclear whether their presence in the bloodstream can be consistently detected and utilized as a clinical marker to guide therapeutic anticancer regimens. To address these questions, we conducted a retrospective study involving 228 patients diagnosed with six different types of carcinomas (colon, gastric, NSCLC, breast, anal canal, kidney), with the majority of them (70%) being non-metastatic. Employing a highly sensitive liquid biopsy approach, ISET®, and cytopathological readout, we isolated and detected circulating PGCCs in the patients’ blood samples. PGCCs were identified in 46 (20.18%) out of 228 patients, including in 14.47% of 152 non-metastatic and 29.85% of 67 metastatic cases. Patients were subsequently monitored for a mean follow up period of 44.74 months (95%CI: 33.39–55.79 months). Remarkably, the presence of circulating PGCCs emerged as a statistically significant indicator of poor overall survival. Our findings suggest that circulating PGCCs hold promise as a reliable prognostic indicator. They underscore the importance of further extensive investigations into the role of circulating PGCCs as a prognostic marker and the development of anti-PGCC therapeutic strategies to improve cancer management and patient survival.
Prostate cancer is the third cause of cancer-related deaths in men. Its early and reliable diagnosis is still a public health issue, generating many useless prostate biopsies. Prostate cancer cells detected in urine could be the target of a powerful test but they are considered too rare. By using an approach targeting rare cells, we have analyzed urine from 45 patients with prostate cancer and 43 healthy subjects under 50 y.o. We observed a relevant number of giant cells in patients with cancer. Giant cells, named Polyploid Giant Cancer Cells (PGCC), are thought to be involved in tumorigenesis and treatment resistance. We thus performed immune-morphological studies with cancer-related markers such as α-methylacyl-CoA racemase (AMACR), prostate-specific membrane antigen (PSMA), and telomerase reverse transcriptase (TERT) to understand if the giant cells we found are PGCC or other urinary cells. We found PGCC in the urine of 22 patients, including those with early-stage prostate cancer, and one healthy subject. Although these results are preliminary, they provide, for the first time, clinical evidence that prostate cancers release PGCC into the urine. They are expected to stimulate further studies aimed at understanding the role of urinary PGCC and their possible use as a diagnostic tool and therapeutic target.
There is an unmet need for reliable biomarkers to predict prostate cancer recurrence after prostatectomy in order to better guide the choice of surgical treatment. We have evaluated the predictive value of the preoperative detection of Circulating Tumor Cells (CTC) for prostate cancer recurrence after surgery. A cohort of 108 patients with non-metastatic prostate adenocarcinoma undergoing radical prostatectomy was tested for the presence of CTC before prostatectomy using ISET®. Disease recurrence was assessed by the increase in serum PSA level after prostatectomy. The following factors were assessed for statistical association with prostate cancer recurrence: the presence of CTC, serum PSA, Gleason score, and pT stage using univariate and multivariate analyses, with a mean follow-up of 34.9 months. Prostate cancer recurrence was significantly associated with the presence of at least 1 CTC at the preoperative time point (p < 0.001; Predictive value = 0.83). Conversely, the absence of prostate cancer recurrence was significantly associated with the lack of CTC detection at diagnosis (Predictive value = 1). Our multivariate analysis shows that only CTC presence is an independent risk factor associated with prostate cancer recurrence after prostatectomy (p < 0.001). Our results suggest that CTC detection by ISET® before surgery is an interesting candidate predictive marker for cancer recurrence in patients with non-metastatic PCa.
Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from peripheral blood samples, we looked for cellular markers in 99 patients (158 samples) with MDS and 66 healthy individuals (76 samples) used as controls. We found a total of 680 Giant Cells, defined as cells having a size of 40 microns or larger in 46 MDS patients (80 samples) and 28 Giant Cells in 11 healthy individuals (11 samples). In order to understand if we had enriched from peripheral blood atypical cells of the megakaryocyte line, we studied the Giant Cells using immunolabeling with megakaryocytes and tumor-specific markers. We report that the Giant Cells we found in the peripheral blood of MDS patients primarily express tumor markers. Our results show that Polyploid Giant Cancer Cells (PGCC), similar to those described in solid tumors, are found in the peripheral blood of patients with MDS and suggest the working hypothesis that they could play a role in hematological malignancies.
27 January 2016 in Plasma Sources Science and Technology
This work reports a detailed experimental study of the plasma properties in low pressure RF discharges in hydrogen peroxide and a comparison with argon under the same operating conditions. H 2 O 2 plasmas have been proposed for sterilization purposes. Electrical properties of the discharge were shown to be similar, as for the RF and DC voltages of the driving electrode. Bulk plasma volume remains stable, concentrated in an almost cylindrical region between the two facing electrodes. It was found that the electron temperature is almost uniform across the plasma and independent of the power level. This is higher than in argon discharges: Te = 4.6 ± 0.9 eV versus Te = 3.3 ± 1.1 eV. The plasma density increases almost linearly with the power level and a substantial negative ion component has been ruled out in hydrogen peroxide. Dissociation in the plasma gas phase was revealed by atomic hydrogen and hydroxyl radical emission in the discharge spectra. Emission from hydroxyl and atomic oxygen demonstrates that oxidizing radicals are produced by hydrogen peroxide discharges, revealing its usefulness for plasma processing other than sterilization, for instance to increase polymer film surface energy. On the other hand, argon could be considered as a candidate for the sterilization purposes due to the intense production of UV radiation.
30 June 2021 in International Journal of Design & Nature and Ecodynamics
Plasma process is a promising physical method for sterilization. Due to the lack of suitable plasma diagnostics, installed in the reactors, a general lack of knowledge happens about the gas-phase chemical composition and the influence of operating parameters. The same lack of knowledge happens in case of gas plasma generated from different gases, candidates for sterilization purposes. The aim of this work is to understand the role of different agents acting in the sterilization process, evaluate the effectiveness of different precursor gases and validate the plasma reactor dedicated. A plasma reactor, equipped with an extended set of plasma diagnostics is dedicated to the understanding the role of different agents of gas plasma sterilization process. A microbiological investigation is carried out to evaluate the efficiency of the steps of the process on cultures of Escherichia coli, using both hydrogen peroxide and argon. The effects on the colonies of Escherichia Coli are assessed in terms of species present in the chamber, acquiring the spectra resulting from the exposure of the Petri dish to sterilization. With regard to the sterilization action of Peroxide and Argon plasma, CFUs are counted for each significant point of the cycle and survival curves are provided. Differences emerge between Peroxide and Argon plasma, for action mechanisms and sterilization time. The survival curves show a more effective sterilizing action of Argon plasma. A validation is necessary by an appropriate statistic and by considering more resistant microorganisms. Reactor will be used to evaluate different precursor gases and microorganisms. The use of non-corrosive and non-irritating gas, such as argon, for sterilization purpose implies a simplification of the plant equipment. It would be possible to remove the components for the vaporization and concentration of peroxide, and to eliminate the management of the boxes containing discarded peroxide, managed to date as hazardous wastes and to reduce significantly the risk for health professionals.